We argue that HIF-1α and HIF-2α are likely to play different roles at different stages of tumour formation and progression and that these roles might potentially be modulated by the spectrum of mutations present in each individual ccRCC. The gene discussed is EPAS1; the disease is nonpapillary renal cell carcinoma.